Study Explores Debilitating Childhood Brain Cancer Treatment Options

News and research before hearing about it on CNBC and others. Claim your free 1-week StreetInsider Premium trial here.

A recent study by the St. Jude Children’s Research Hospital and the School of Medicine at Washington University in St. Louis suggests that young patients with an average risk of medulloblastoma, after six weeks of radiation treatment, can receive a radiation boost to a smaller amount. part of the brain.

Medulloblastoma is a pediatric brain cancer that usually affects the spine and/or brain and can spread through a patient’s spinal fluid. The standard treatment for this type of cancer involves radiation to the entire spine and brain, followed by an additional


NOTE TO INVESTORS: The latest news and updates related to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is a biomedical news and content distribution company that (1) provides access to a network of wire services through InvestorWire to most effectively reach all target markets, industries and demographics, (2) syndicate articles and editorial to more than 5,000 news outlets (3), enhanced press releases to ensure maximum impact, (4) social media distribution through the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full suite of corporate communications solutions, and ( 6) a total news reporting solution with BMW Prime. As a multi-faceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies seeking to reach a broad audience of investors, consumers, journalists and the general public. By cutting through the information overload in today’s market, BMW offers its customers unparalleled visibility, recognition and brand awareness. BMW is where news, content and information come together.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (US cell phones only)

For more information, visit

Please see the full terms of use and disclaimers on the BioMedWire website that apply to all content provided by BMW, wherever published or republished:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork.

Comments are closed.